Ozempic, Mounjaro and Your Period: Late, Heavy or Spotting on a GLP-1

No GLP‑1 label lists a change to the menstrual cycle as a side effect, and no trial has measured periods in women without PCOS who take semaglutide or tirzepatide. What does exist is thin and indirect. Adverse-event databases show more reports than expected of heavy bleeding, bleeding between periods and clots, mostly with semaglutide. The labels themselves record longer cycles in female rats that were eating less. In PCOS, losing weight brings ovulation back for many women, which can make periods arrive, change or reappear. A late period on one of these drugs has one cause to rule out before any other: pregnancy.

What the labels say about periods

Nothing, in any of the six. The words menstruation, menstrual, uterine bleeding, amenorrhea and spotting do not appear in the current prescribing information for Wegovy or Ozempic,^[6][7] for Mounjaro or Zepbound,^[8][9] or for Saxenda or Foundayo.^[10][11] The adverse-reaction tables on those labels draw on trials that enrolled thousands of women. Our reading: a common, large effect on bleeding would likely have shown up there. A subtle or uncommon one could easily have been missed.

The nearest thing to a menstrual finding sits in the animal toxicology section. Both semaglutide labels describe it the same way:

In females, an increase in estrus-cycle length was observed at all dose levels, together with a small reduction in numbers of corpora lutea at greater than or equal to 0.03 mg/kg/day, at clinically relevant exposures. These effects were likely an adaptive response secondary to the pharmacological effect of semaglutide on food consumption and body weight.

— Wegovy prescribing information, section 13.1

In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.

— Zepbound prescribing information, section 13.1

In plain terms: rats on either drug ate less, and their reproductive cycles lengthened. Corpora lutea are what an ovary leaves behind after it releases an egg, so fewer of them means fewer ovulations. Both manufacturers put this down to reduced eating rather than a direct effect on the ovary.^[6][8] Rat cycles last four to five days and are not a model for a human period. The finding matters mainly because it points at the same explanation the human data keep returning to: eating much less can change a cycle.

The adverse-event reports

The only evidence specifically about periods in ordinary users comes from the FDA Adverse Event Reporting System (FAERS), where patients, clinicians and manufacturers report problems they suspect a drug caused. Four analyses have looked at it. They are disproportionality studies: they ask whether a reaction is reported more often with one drug than with others in the same database. That can flag a signal worth studying. It cannot show that a drug caused the reaction, and it cannot say how often the reaction happens.

• Obstetrics & Gynecology, 2026. Looking only at reports for women aged 12 to 55, semaglutide showed more reports than expected of heavy menstrual bleeding, bleeding between periods, clots, infrequent periods and cycles without ovulation. Tirzepatide showed signals for bleeding between periods and clots. Liraglutide showed none.^[1]
• Diabetes/Metabolism Research and Reviews, 2026. Semaglutide was again reported disproportionately for menstrual abnormalities. Tirzepatide went the other way: painful periods, absent periods and heavy bleeding were reported less often than expected.^[2]
• Cureus, 2026. Comparing the two drugs head to head across 103,607 reports involving women, gynecological bleeding appeared in 0.60% of tirzepatide reports and 0.62% of semaglutide reports, a reporting odds ratio of 0.97, no difference. Almost all tirzepatide reports (94.6%) came from consumers, against about half for semaglutide.^[3]
• Drug, Healthcare and Patient Safety, 2026. A tirzepatide-only analysis listed postmenopausal bleeding and menstrual disorder among signals it described as new.^[4]

Raw counts from the public FAERS feed give a sense of scale. These are reports that name the drug and the reaction, as of the database’s July 2026 update; one report can list several drugs and several reactions.^[5]

Against more than a quarter of a million reports in total, a few hundred about bleeding is a small slice. It is not nothing, and one gynecology journal’s authors argued that menstrual health belongs in the counseling conversation for women of reproductive age.^[1]

Three plausible reasons a cycle could change

None of the following has been tested as a cause of period changes on a GLP‑1. Each is an inference from what is known about weight, food intake and hormones, and they can pull in opposite directions.

Losing weight can restart ovulation

Excess weight is a common reason ovulation becomes irregular, and losing some of it often brings ovulation back. In a small 1995 study of a six-month diet and exercise program, 12 of 13 women who had not been ovulating began to again after losing an average of 6.3 kg, and 11 became pregnant.^[12] On semaglutide, an uncontrolled 2026 clinic series followed 96 women with PCOS and overweight for six months. They lost 11.3% of their weight, and 52.5% of those who had not been ovulating began having ovulatory cycles.^[13] A registered review of the randomized trials in PCOS still judged the evidence on menstrual regularity too thin to draw a conclusion.^[14]

For someone whose periods were sparse or absent, a returning cycle can look like a side effect: a period after months without one, an unpredictable bleed while the cycle resets, or a heavier flow after a long gap. That is an interpretation, not a measured finding. The PCOS evidence and the narrow trial record on fertility are covered separately.

Eating very little can suppress it

The opposite also happens. The Endocrine Society describes functional hypothalamic amenorrhea, in which periods stop without any structural cause, as often tied to stress, weight loss, intense exercise, or a mix of them, and treats it as a diagnosis made only after other causes are excluded.^[15] A GLP‑1 can cut intake sharply, especially in the early months and after each dose increase. Whether that is ever enough to suppress ovulation in people starting with excess weight has not been studied. It is the human version of what the rat sections of the labels describe. Fast loss has other costs too, covered in hair loss and muscle loss on a GLP-1.

The pill may be absorbed differently

The tirzepatide labels report that a single 5 mg dose cut peak blood levels of the estrogen in a combined pill by 59% and of its progestin by 66%, with total exposure falling by about 20%.^[8][9] Low or erratic hormone levels from the pill are a familiar cause of breakthrough spotting, so a link is plausible. No study has checked whether people on tirzepatide and the pill spot more. The labels’ concern is pregnancy, not bleeding, and the advisory and its timing are set out in GLP-1 drugs and hormonal birth control. Vomiting soon after taking a pill can have a similar effect with any GLP‑1.

A late period: rule out pregnancy first

Before reading a late period as a drug effect, take a pregnancy test. The reasons stack up. Ovulation can return before anyone expects it. On Mounjaro or Zepbound, the pill itself may be less reliable for a month at the start and for a month after every step up in dose; the labels tell pill users to change method or use condoms as backup during those windows.^[8][9] And the labels treat pregnancy as a reason to act. Zepbound’s says to stop once pregnancy is recognized. The semaglutide labels set a gap of two months or more between the last dose and trying to conceive.^[8][6]

If the test is positive, contact the prescriber rather than simply carrying on. What is known about exposure in early pregnancy is set out in GLP-1 drugs, pregnancy and trying to conceive. A 2026 international consensus review of incretin drugs and reproduction found evidence for only about half of the questions it set out to answer, and only two studies on contraception.^[22]

Cramps and painful periods

There is almost nothing on this. One published case describes a woman whose severe period pain, unresponsive to usual treatment, eased on semaglutide without any weight change; the authors called for a trial.^[18] In the adverse-event data, painful periods were reported less often than expected with tirzepatide in one analysis.^[2] Neither tells you what to expect. Nausea, bloating and constipation are common on these drugs, and abdominal cramping from the gut can be hard to tell apart from period pain. How long GLP-1 side effects last covers when the digestive ones tend to peak.

A curious animal finding runs the other way: female rats given liraglutide or semaglutide in certain phases of their cycle ate less and lost more weight than those dosed in other phases.^[19] Whether appetite suppression varies across the human cycle has not been tested.

Bleeding after menopause is not a side effect to wait out

Any vaginal bleeding after menopause needs prompt assessment, whatever drug someone is taking. ACOG notes that bleeding is the first sign in more than 90% of postmenopausal women with endometrial cancer, and that excess weight, type 2 diabetes and PCOS, all common among people prescribed these drugs, raise that risk.^[20]

A 2026 case report describes a 58-year-old woman who began bleeding six weeks after starting semaglutide, following a dose increase to 0.5 mg. Her hemoglobin fell from 12.9 to 10.8 g/dL. Cancer, structural causes and clotting disorders were ruled out first, and the bleeding stopped within five weeks of stopping the drug. The authors rated the link “probable” on a standard scale and proposed, without proving, that rapid fat loss changed how estrogen is handled in the body.^[16] An earlier report describes a 44-year-old in perimenopause with heavy bleeding a week after a second dose of dulaglutide, which stopped when the drug did.^[17] Single cases cannot establish cause. The order of investigation in that 2026 case is the lesson: cancer was excluded before the drug was blamed. More on weight and the menopause years is in GLP-1 drugs after menopause.

When to call a clinician

These thresholds come from CDC guidance on heavy menstrual bleeding and from ACOG on bleeding after menopause.^[21][20] None depends on whether a GLP‑1 is involved.

• Soaking through one or more pads or tampons every hour for several hours in a row, or needing a new one in under 2 hours.
• A period lasting more than 7 days, or clots the size of a quarter or larger.
• Feeling tired, weak or short of breath during or after heavy bleeding, which can mean anemia.
• Any bleeding at all after menopause.
• A missed period with a positive pregnancy test, or a missed period plus pelvic pain or one-sided pain.
• Bleeding heavy enough to cause dizziness or fainting. That needs urgent care, not an appointment.

Bring dates. A note of when each bleed started, when the drug was started and when each dose was increased makes it much easier for a clinician to judge whether the timing fits.

What nobody has measured

• How often periods change in women without PCOS on semaglutide or tirzepatide. No trial has reported it.
• Whether any change is due to the drug, to weight loss, to eating less, or to an interaction with the pill.
• Whether the signals in the adverse-event database reflect a real effect. They conflict for tirzepatide and rest heavily on consumer reports.
• Whether bleeding changes settle once the dose is stable. Plausible, since dose increases are when intake and pill absorption change most, but unstudied.